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OBJECTIVE—The E23K variant in the Kir6.2 subunit of the
ATP-sensitive K
 channel (KATP channel) is associated with
increased risk of type 2 diabetes. The present study was under-
taken to increase our understanding of the mechanisms respon-
sible. To avoid confounding effects of hyperglycemia, insulin
secretion and action were studied in subjects with the variant
who had normal glucose tolerance.
RESEARCH DESIGN AND METHODS—Nine subjects with
the E23K genotype K/K and nine matched subjects with the E/E
genotype underwent 5-h oral glucose tolerance tests (OGTTs),
graded glucose infusion, and hyperinsulinemic-euglycemic clamp
with stable-isotope–labeled tracer infusions to assess insulin
secretion, action, and clearance. A total of 461 volunteers con-
secutively genotyped for the E23K variant also underwent
OGTTs. Functional studies of the wild-type and E23K variant
potassium channels were conducted.
RESULTS—Insulin secretory responses to oral and intravenous
glucose were reduced by 40% in glucose-tolerant subjects
homozygous for E23K. Normal glucose tolerance with reduced
insulin secretion suggests a change in insulin sensitivity. The
hyperinsulinemic-euglycemic clamp revealed that hepatic insulin
sensitivity is 40% greater in subjects with the E23K variant, and
these subjects demonstrate increased insulin sensitivity after
oral glucose. The reconstituted E23K channels conﬁrm reduced
sensitivity to inhibitory ATP and increase in open probability, a
direct molecular explanation for reduced insulin secretion.
CONCLUSIONS—The E23K variant leads to overactivity of the
KATP channel, resulting in reduced insulin secretion. Initially,
insulin sensitivity is enhanced, thereby maintaining normal glu-
cose tolerance. Presumably, over time, as insulin secretion falls
further or insulin resistance develops, glucose levels rise result-
ing in type 2 diabetes. Diabetes 58:1869–1878, 2009
T
he ATP-sensitive K
 channel (KATP channel)
plays a central role in glucose-stimulated insulin
secretion (GSIS). It is comprised of two sub-
units, an inward rectiﬁer potassium channel
(Kir6.2) and a sulfonylurea receptor (SUR1). An increase
in the cytosolic ATP-to-ADP ratio in the pancreatic -cell
inhibits KATP channel activity and stimulates insulin secre-
tion, whereas a lowering of the ATP-to-ADP ratio restores
channel activity and suppresses insulin release. Mutations
in the genes encoding Kir6.2 (KCNJ11) and SUR1
(ABCC8) are associated with neonatal diabetes mellitus
(NDM) and hyperinsulinism (1,2). A common amino acid
polymorphism in Kir6.2, Glu23Lys (E23K), is associated
with susceptibility to type 2 diabetes (3). However, the
mechanistic basis of this association and the phenotypic
consequences in vivo remain controversial. An early study
(4) observed no effects of the E23K variant on whole-cell
K
 currents. Conversely, more detailed studies report
overactivity of E23K channels that is variably attributed to
a decrease in channel sensitivity to inhibitory ATP (5) or
an increase in ATP sensitivity with an enhanced activation
by free fatty acids (6). In both cases, net overactivity of the
KATP channel is predicted to suppress GSIS.
Although initial studies in humans showed no changes
in insulin secretion, subsequent studies (7–9) showed
association of the E23K variant with reduced insulin
secretion. If these studies are performed on diabetic
subjects, reduced insulin secretion may result from the
adverse effects of hyperglycemia on -cell function. The
present study was performed in order to provide quan-
titative indexes of insulin secretion and deﬁne dose-
response relationships between glucose and insulin
secretion rate (ISR) at various glucose concentrations in
subjects with the E23K genotype and normal glucose
levels. The contribution of alterations in insulin clear-
ance to insulin levels as a function of the E23K genotype
was also examined.
It is unclear whether the KATP channel regulates insulin
sensitivity. Although an increase in insulin sensitivity is
reported in animals with loss of KATP channels (10),
similar studies have not been performed with gain of
channel activity. A study in human subjects (11) suggested
that the E23K genotype underlies an increase in insulin
sensitivity, whereas insulin sensitivity was not altered in
other studies (8,12–14). The present study was undertaken
to address these gaps in our understanding of the physio-
logical mechanisms underlying susceptibility to type 2
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glycemia can cause defects in insulin secretion, we fo-
cused on subjects with normal glucose tolerance. This
allowed us to deﬁne the changes in insulin secretion and
action that antedate diabetes onset and are due to the
effects of the E23K variant per se. To resolve questions
regarding the underlying mechanisms, we performed com-
prehensive assessments of the effect of E23K on KATP
channel activity.
RESEARCH DESIGN AND METHODS
Nondiabetic subjects, aged 65 years in good health and with stable weight
for 6 months, were recruited using advertisements. The studies were approved
by the Human Research Protective Ofﬁce.
Study 1 (intensive metabolic studies). Nine subjects with the K/K geno-
type and nine age-, sex-, and BMI-matched subjects with the E/E genotype
participated in three separate protocols designed to test insulin secretion,
action, and clearance. All subjects were unrelated and had no family history of
type 2 diabetes. Insulin secretion was assessed using the 5-h oral glucose
tolerance test (OGTT) and graded glucose infusion (GGI). Insulin sensitivity
was assessed during the hyperinsulinemic-euglycemic clamp and OGTT.
Insulin clearance was assessed during OGTT and GGI.
Study 2 (cross-sectional study). A total of 461 volunteers who responded
to advertisements were genotyped for the E23K variant and underwent 5-h
OGTTs for assessments of insulin secretion, action, and clearance.
Study protocols. Subjects adhered to their regular diet and refrained from
exercise for 3 days before the studies.
5-h OGTT. Participants ingested a 75-g glucose load. Blood samples were
collected at 15, 0, 10, 20, 30, 60, 90, 120, 150, 180, 240, and 300 min after
ingestion to determine plasma glucose, insulin, and C-peptide concentrations.
GGI involved the intravenous administration of glucose at increasing rates (1,
2, 3, 4, 6, and 8 mg  kg
1  min
1) for 40 min each (15,16). This protocol raises
the plasma glucose concentration from basal to hyperglycemic levels and
deﬁnes the dose-response relationships between glucose and insulin
secretion.
Hyperinsulinemic-euglycemic clamp with stable-isotope–labeled tracer
infusion. Studies (17,18) were performed after an overnight fast as described.
A primed (22.5 mol/kg)-constant (0.25 mol  min
1  kg
1) infusion of
[6,6-
2H2]glucose was started at 0700 h. After 3.5 h of tracer infusion, a
hyperinsulinemic-euglycemic clamp was started and continued for 3.5 h.
Insulin was infused at 40 mU/m
2 per min. Dextrose (20%) with [6,6-
2H2]glucose
(2.5%) was infused to maintain plasma glucose concentration at 5.6
mmol/l. The infusion of [
2H2]glucose was decreased by 75% of basal during the
clamp for the expected decline in hepatic glucose production. Body compo-
sition was assessed using the same dual-energy X-ray absorptiometry instru-
ment in all subjects (Delphi 4500-W; Hologic, Waltham, MA).
Analyses. The areas under the curve (AUCs) were calculated using the
trapezoid method (19). ISR was calculated using parameters for C-peptide
kinetics and volume of distribution (20). Static, dynamic, and overall respon-
sivity indexes were calculated as reported (21). The GGI allowed the
dose-response relationship between ISR and glucose over the physiological
range to be determined. ISRs and glucose concentrations represented the
average of the values between 10 and 40 min at each infusion rate. Mean ISR
for each glucose infusion rate was plotted against the mean glucose concen-
tration. The slope of the line relating these two variables provided a measure
of the sensitivity of the -cell to glucose. Peripheral insulin sensitivity was
calculated from the hyperinsulinemic-euglycemic clamp (17,18,22). Basal
endogenous glucose rate of appearance was calculated using Steele’s equa-
tions (20). Hepatic insulin sensitivity was assessed as the inverse of the
product of the basal endogenous glucose production rate (mol  kg fat-free
mass
1  min
1) and the fasting insulin concentration (pmol/l)  1,000 (23,24).
Whole-body insulin sensitivity was estimated using the oral glucose minimal
model (25,26). Composite insulin sensitivity index was calculated using the
method of Matsuda (23). Insulin clearance rate was calculated by dividing the
1) ISR AUC by the insulin AUC and the 2) C-peptide AUC by the insulin AUC
(15,27).
Biochemical measurements. Plasma glucose was measured using a glucose
analyzer (Yellow Springs Instruments, Yellow Springs, OH). Plasma insulin
and C-peptide were measured using radioimmunoassays (Linco Research,
St.Louis, MO).
Genotyping. DNA was prepared from peripheral blood lymphocytes and the
KCNJ11 E23K polymorphism (dbSNP rs5219) typed using a TaqMan SNP
Genotyping Assay (Applied Biosystems, Foster City, CA).
Statistical analyses. Group differences were compared using the Student’s t
test for unpaired samples for continuous variables and the Fisher’s exact test
for categorical variables. Where appropriate, we used ANOVA and Tukey’s
test for post hoc analyses for continuous variables and 
2 test for categorical
variables. ANCOVA were used to adjust for age, race, and BMI. SPSS version
15.0 (SPSS, Chicago, IL) was used for all analyses. A P value 0.05 was
considered to be statistically signiﬁcant. Results are reported as means 	 SE.
In vitro studies of the E23K variant. Recombinant KATP channel Kir6.2
(mouse)  SUR1 (hamster) was transiently expressed in COSm6 cells as
described (28). Of the missense variants reported in humans, the Kir6.2 clone
contained no variants, while the SUR1 clone contained the A1369S substitu-
tion. Patch-clamp experiments were performed as described (28). Bath and
pipette solutions (K-INT) contained (in mmol/l): 150 KCl, 10 HEPES, and 1
EGTA (pH 7.4). For experiments with MgATP, the free Mg
2 concentration
was kept at 2 mmol/l. The ATP dose response was quantiﬁed by ﬁtting the raw
data with a Hill equation:
Irel 
 1/(1  [{ATP}/K1/2,ATP]
H)
where Irel is the current relative to that in the absence of ATP, {ATP} is the
ATP concentration, K1/2,ATP is the half-maximal inhibitory ATP concentration,
and H is the Hill coefﬁcient, which was allowed to vary. Dose-response curves
for tolbutamide inhibition were described by the product of two Hill compo-
nents (28), where A represents the high-afﬁnity and B the low-afﬁnity
components:
Irel 
 ([1  l]  L/[1  [{Tolb}/K1/2A]
HA)
 (1/[1  [{Tolb}/K1/2B]
HB)
where {Tolb} is the tolbutamide concentration, K1/2A and K1/2B are the
half-maximal inhibitory tolbutamide concentrations, HA and HB are the Hill
coefﬁcients, and l is the fraction of current blocked with high afﬁnity.
86Rb
 efﬂux experiments were performed as described (28). Transfected
cells were preincubated with or without metabolic inhibitors (2.5 g/ml
oligomycin plus 1 mmol/l 2-deoxy-D-glucose). At selected time points, the
solution was aspirated and replaced with fresh solution and the aspirated
solution was counted in a scintillation counter. The rate constant of ATP-
sensitive K
–speciﬁc (
86Rb
) efﬂux (k2) was obtained by ﬁtting the data with
a single exponential equation:
Relative ﬂux 
 1  exp [ (k1  k2)  t]
where the rate constant for nonspeciﬁc efﬂux (k1) was obtained from
untransfected cells.
Two approaches were used to estimate Po,zero, the initial open probability
(in zero ATP), of membrane patches containing multiple channels. (PIP2;
method I) PIP2 was added to the patch until the current reached a saturating
level (IPIP2). This was assumed to represent a maximum Po,zero of 0.97 (29).
The fold increase in current was calculated (fold increase 
 IPIP2/Iinitial) and
the Po,zero was estimated from the following equation:
Po,zero 
 0.97/( fold increase)
(NA; method II) Mean Po,zero was estimated from stationary ﬂuctuation
analysis of macroscopic currents (30,31). Mean patch current (I) and variance
(
2) in the absence of ATP were obtained by subtraction of the mean current
and variance in 5 mmol/l ATP (i.e., all channels closed), respectively.
Single-channel current (i) was assumed to be 3.75 pA, corresponding to
single-channel conductance of 75 pS. Po,zero was estimated from the following
equation:
Po,zero 
 1  (
2)/[i  I]).
Channel density was calculated as I(Po,max  i) from maximum patch
current in zero ATP (I) and assuming a single-channel current (i) 
 3.75 pA
at 50 mV.
RESULTS
Insulin secretion in subjects with E23K variant. We
initially examined insulin secretion in subjects homozy-
gous for the E23K variant, since they might exhibit the
greatest difference if E23K genotype affected insulin secre-
tion. The two groups were well matched for age, sex, and
BMI (Table 1). Both groups had normal glucose concen-
trations in the fasting state and following oral and intra-
venous glucose administration (Table 1) (Fig. 1). The
respective AUCs for glucose between E/E and K/K subjects
during the OGTT (17.6 	 0.1 vs. 18.7 	 0.1  10
4 min 
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1  l
1) and GGI (17.6 	 0.1 vs. 17.6 	 0.1  10
4 min 
mmol
1  l
1) were not different (Fig. 1). By contrast, the
AUC for insulin in the OGTT (52.6 	 5.7 vs. 71.0 	 7.0 
10
3 min  pmol
1  l
1) and GGI (24.5 	 2.1 vs. 36.1 	 4.8 
10
3 min  pmol
1  l
1) was 40% lower (P  0.05) in the K/K
group. The AUC for C-peptide was also reduced (P  0.05) in
the K/K subjects in both the OGTT (30.2 	 2.7 vs. 58.9 	
15.1  10
4 min  pmol
1  l
1) and GGI (26.4 	 2.1 vs. 36.9 	
3.3  10
4 min  pmol
1  l
1). Static, dynamic, and overall
-cell response to glucose were also 40% lower (P  0.05)
in the K/K group (Fig. 2A) based on the OGTT and GGI. In
addition, the dose-response curve relating glucose and ISR
during the GGI was shifted downward and to the right in the
K/K group (Fig. 2B). Accordingly, the ISR AUC (17.2 	 1.2 vs.
26.1 	 0.5  10
3 pmol/l) and mean ISR (70.6 	 4.9 vs. 106.7 	
9.9 pmol l
1min
1) were lower (P0.05) in the K/K group.
No signiﬁcant differences were observed in insulin clearance
rates in this study (P  0.05).
Alterations in ATP sensitivity of reconstituted E23K
channels in vitro. To examine the molecular basis for the
differences in insulin secretion, we transiently expressed
Kir6.2 with residue 23, being either glutamate (E23) or
lysine (K23), together with the SUR1 subunit and mea-
sured ATP sensitivity in excised membrane patches (Fig.
3A). Homomeric K23 channels (K/K) exhibit a modest, yet
signiﬁcant, decrease in ATP inhibition compared with
homomeric E23 (E/E) channels (K1/2,ATP 
 16 mol/l [n 

TABLE 1
Characteristics of study participants (study 1)
E/E K/K P value
n 99
Women (%) 6 (67) 6 (67) 1.0
Caucasian (%) 9 (100) 9 (100) 1.0
Age (years) 45.9 	 2.8 46.6 	 3.9 1.0
Weight (kg) 75.5 	 5.7 72.9 	 4.2 0.73
Height (cm) 166.1 	 2.5 164.2 	 3.9 0.69
BMI (kg/m
2) 27.8 	 1.3 26.4 	 1.6 0.53
Fat mass (kg) 31.1 	 6.1 22.0 	 3.0 0.20
Fat-free mass (kg) 43.7 	 3.6 49.2 	 3.7 0.30
Truncal fat (kg) 13.4 	 1.8 10.0 	 1.7 0.20
Fasting glucose (mmol/l) 5.1 	 0.2 5.2 	 0.1 0.73
2-h glucose (mmol/l) 6.9 	 0.3 6.8 	 0.3 0.62
A1C (%) 5.6 	 0.1 5.5 	 0.2 0.72
Data are means 	 SE.
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FIG. 1. Plasma glucose insulin and C-peptide concentrations during the oral glucose tolerance test (A) and intravenous GGI (B) in the K/K (E)
and E/E (F) groups. P values indicate the signiﬁcance of the differences between AUC values between groups. Values are means  SE.
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 24 patches], respectively).
A similar relative shift in ATP sensitivities was observed in
the presence of physiological (2 mmol/l) Mg
2 for E/E and
K/K channels (K1/2,ATP 
 19 mol/l [n 
 19 patches] and 26
mol/l [n 
 17 patches], respectively). In contrast, the
averaged KATP channel density was not different between
cells expressing E/E or K/K channels (201 	 59 and 128 	
50 channels/patch, respectively; n 
 11–19 patches). To
recapitulate the heterozygous E23K genotype (E/K), cells
were transfected with a 1:1 mixture of E/E and K/K cDNAs.
Since four subunits generate the channels, ﬁve different
ratios of subunits will be present in the resultant channels
(1 of 16 channels will be homozygous E/E and homozy-
gous K/K). The ensemble of expressed channels display
intermediate ATP sensitivity (K1/2,ATP 
 10.0 mol/l [n 

10 patches] compared with homomeric K/K and E/E
channels) (Fig. 3B). Our data are similar to those reported
by Schwanstecher et al. (5) for recombinant K/K channels.
For comparison, the dose-response curves are shown in
Fig. 3B for two Kir6.2 mutations that impair insulin release
and underlie NDM. The I182V mutation underlies a tran-
sient NDM, whereas the I296L mutation underlies a syn-
dromic form of NDM (32,33). Importantly, the ATP
sensitivities of mutant channels correlate with the severity
of the disease (K1/2,ATP 
 39 mol/l for homomeric I182V
[n 
 17 patches] and 771 mol/l for homomeric I296L
channels [n 
 5 patches]).
Increased cellular activity of reconstituted E23K
channels. KATP channel activity in metabolically intact
cells was screened by
86Rb
-efﬂux from transfected
COSm6 cells. Efﬂux from cells transfected with homo-
meric E/E channels was low under basal conditions and
was activated by metabolic inhibition to lower cellular
[ATP]/[ADP] (Fig. 4A). Rb
-efﬂux from cells transfected
with recombinant K/K channels was also low under basal
conditions and increased with metabolic inhibition. Quan-
titative estimation of KATP channel conductance (see RE-
SEARCH DESIGN AND METHODS) indicates that for K/K channels,
basal conductance was a higher fraction of fully activated
conductance than E/E channels (Fig. 4B). In the -cell, the
increased basal ﬂux is expected to impair glucose sensing
and account for the association of K/K genotype with
reduced insulin secretion.
E23K variant decreases ATP sensitivity by stabilizing
the open state of the channel. Kir6.2 mutations can
reduce ATP sensitivity by directly reducing ATP binding to
the Kir6.2 subunit or indirectly by affecting the intrinsic
opening ability (28,29,34). In the latter case, an increase in
the open probability (Po,zero) decreases the frequency with
which the channel enters the ATP-accessible closed
state, resulting in a decrease in ATP sensitivity. We have
modeled this nonlinear relationship between Po,zero and
K1/2,ATP (29), and this kinetic model describes the diabe-
tes-causing effects of Kir6.2 mutations that underlie NDM
(e.g., Q52R, I296L) (Fig. 5C). To estimate the open proba-
bility of KATP channels, both nonstationary noise analysis
(NA) and phosphatidylinositol biphosphate (PIP2) applica-
tion were used to independently examine KATP channel
gating in isolated membrane patches. As shown in Fig. 5A,
the estimated open probability (Po,zero) of K/K channels in
the absence of ATP (0.68 	 0.04 [NA method]; 0.67 	 0.08
[PIP2 method]) is higher than that of E/E channels (0.49 	
0.05 [NA method]; 0.46 	 0.06 [PIP2 method], P  0.05),
and this increase can fully account for the shifted ATP
sensitivity (K1/2,ATP 
 9.4 	 1.6 mol/l [E/E] and 21.6 	 3.3
mol/l [K/K] from curve ﬁt of individual membrane
patches, P  0.01) (Fig. 5B). A similar increase in open
probability was reported for K/K channels by Schwan-
stecher et al. (5), using analysis of single-channel records.
That multiple methodologies reiterate the same ﬁndings
strengthens the conclusion that the changes associated
with the E23K variant are signiﬁcant and real. As with
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FIG. 2. A: Insulin secretory indexes during the OGTT and intravenous
GGI in the K/K () and E/E groups (f). *P < 0.05 for the differences
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sensitivity by increasing the Po,zero (Fig. 5C). The predicted
consequence will be reduced excitability of the -cell, with
increasingly severe consequences for insulin secretion
(E23K  Q52R  I296L).
Sulfonylurea sensitivity is reduced in E23K channels.
Mutations in Kir6.2 that allosterically decrease ATP sensi-
tivity by stabilizing the open state of the channel also
reduce high-afﬁnity block by sulfonylureas, a feature of
NDM-associated mutations (28). We next examined the
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channel activity (Fig. 3C). As shown in Fig. 3D, homomeric
E/E channels exhibit a typical biphasic block by tolbut-
amide, with both a high-afﬁnity (IC50 
 1.1 mol/l) and a
low-afﬁnity (IC50 
 2 mmol/l) site. The fractional block by
the high-afﬁnity therapeutically relevant component is
53%. For the K/K channels, the value for the high-afﬁnity
block (IC50 
 1.0 mol/l) is unaltered; however, the
fractional block is signiﬁcantly decreased from 53 to 44%.
Insulin sensitivity in subjects with the E23K variant.
The clinical ﬁndings described above (of reduced insu-
lin secretion with normal glucose concentrations)
suggest a simultaneous change in insulin sensitivity.
Hyperinsulinemic-euglycemic clamp experiments re-
vealed that hepatic insulin sensitivity was signiﬁcantly
greater (2.4 	 0.4 vs. 1.5 	 0.2 [1,000/mol  kg fat-free
mass
1  min
1  pmol
1  l
1]; P  0.05) in subjects with
the K/K genotype (Fig. 6A). There was also a strong trend
(0.19 	 0.03 vs. 0.14 	 0.2 mol  kg fat-free mass
1  min
1
 pmol
1  l
1; P  0.10) for an increase in peripheral
insulin sensitivity, although the differences were not sta-
tistically signiﬁcant. Similar trends were observed for
whole-body insulin sensitivity as assessed from the OGTT
(Fig. 6B). Glucose infusion rate, plasma glucose, insulin,
glucagon, and tracer-to-tracee ratio are presented in the
online appendix (available at http://diabetes.diabetes
journals.org/cgi/ content/full/db09-0025/DC1).
Conﬁrmation of changes of insulin secretion and
action. The human studies described above were con-
ducted in a small group of E/E or K/K subjects. To conﬁrm
the ﬁndings on insulin secretion and action in a larger
cohort, we carried out 5-h OGTTs in 461 additional sub-
jects (Table 2). Subjects were divided into three groups
based on E23K genotype. The three groups had similar
glucose concentrations during fasting and 2-h post-glucose
challenge. The relative frequencies of E/K (40%) and K/K
(13%) in our sample are comparable with those reported
(7,8,35), conferring a relative diabetes risk of 1.15–1.65 (3).
Consistent with the above ﬁndings, the K/K subjects had
reduced insulin and C-peptide concentrations, reduced
insulin secretory responses, reduced -cell responsiveness
to glucose, and enhanced insulin sensitivity and clearance
rates. Interestingly, -cell responsiveness was also lower
in the E/K variant than the E/E.
DISCUSSION
Association of Kir6.2 E23K variant with impaired
insulin secretion. Type 2 diabetes is a multifactorial
disease in which genetic and environmental factors inter-
act to determine the level of predisposition, and, recently,
genome-wide association studies have identiﬁed common
polymorphisms in various genes that are associated with
increased diabetes susceptibility (2,36–39). These studies
often involve the comparison of genetic and phenotypic
characteristics of diabetic and control subjects. They have
made important contributions to identifying novel genetic
loci that determine diabetes risk. However, studies of
subjects with diabetes do not provide information on the
effects of the respective polymorphisms prior to the onset
of glucose intolerance and diabetes. Since hyperglycemia,
per se, adversely affects insulin secretion, it is difﬁcult to
differentiate between the effects of hyperglycemia and the
effects of the polymorphism in studies of established
diabetes.
The present study was focused on subjects without a
prior history of diabetes who had normal glucose toler-
ance. Our results demonstrate that the Kir6.2 E23K variant
is associated with multiple insulin secretory defects, in-
cluding a reduction in overall -cell responsiveness to
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between glucose and insulin secretion. Overall insulin
secretory responses to glucose were reduced by 40%,
and the extent of the reduction was similar to both oral
and intravenous glucose.
Association of E23K variant with enhanced insulin
sensitivity. We did not anticipate that severe reductions
in insulin secretion would be compatible with normal
glucose tolerance. The signiﬁcant increase in insulin
sensitivity is presumably the mechanism that makes this
possible, and the results of the hyperinsulinemic-eugly-
cemic clamp suggest that the major effects are in the
liver. This is the ﬁrst study to report the coexistence of
decreased insulin secretion with increased insulin ac-
tion in subjects with the E23K polymorphism. Previous
studies that evaluated insulin action yielded inconsis-
tent results. One study (11) suggested an increase in
insulin sensitivity, while others (8,12,13) found no ef-
fect. Moreover, ﬁndings from the hyperinsulinemic
clamp suggested an increase in peripheral (skeletal
muscle) insulin sensitivity, although this did not reach
statistical signiﬁcance (P  0.10) because of the small
sample size. This interpretation is supported by the
results obtained in the larger cohort study in which
statistically signiﬁcant increases in insulin sensitivity
were observed after oral glucose ingestion. Although
BMI was different between groups, measurements of
total and regional fat (truncal fat) showed no differ-
ences. Nevertheless, because of the differences in BMI,
we controlled for BMI using ANCOVA. The differences
in insulin sensitivity remained signiﬁcant (P  0.001),
despite similar and normal glucose tolerance.
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TABLE 2
Characteristics of study participants (study 2)
Kir6.2 genotype
E/E E/K K/K P value
n 216 184 61
Women (%) 158 (73) 120 (65) 45 (74) 0.40
Caucasian (%) 127 (59) 155 (84) 55 (90) 0.001
Age (years) 38.0 	 0.9 38.2 	 1.1 36.6 	 12.4 0.74
BMI (kg/m
2) 29.5 	 0.5 27.5 	 0.5* 27.1 	 0.9* 0.001
Fat mass (kg) 33.5 	 0.7 31.9 	 0.7 31.8 	 1.3 0.23
Truncal fat (kg) 13.2 	 0.5 12.2 	 0.4 11.4 	 0.9 0.16
A1C (%) 5.6 	 0.0 5.5 	 0.0* 5.5 	 0.1* 0.002
OGTT
Fasting glucose (mmol/l) 5.3 	 0.1 5.1 	 0.0 5.2 	 0.1 0.28
2-h glucose (mmol/l) 7.8 	 0.1 7.6 	 0.1 7.4 	 0.2 0.43
Glucose AUC  10
4 (min  mmol
1  l
1) 19.6 	 0.2 19.1 	 0.3 18.8 	 0.4 0.34
Insulin AUC  10
3 (min  pmol
1  l
1) 90.2 	 4.2 73.6 	 3.5 62.5 	 4.9* 0.001
C-peptide AUC  10
4 (min  pmol
1  l
1) 51.6 	 1.4 48.9 	 1.3 43.4 	 2.2* 0.010
Insulin sensitivity (SI)
SIMM  10
4 (dl  kg
1  min
1  pmol
1  l
1)† 1.7 	 0.1 1.8 	 0.7 2.6 	 0.2† 0.001
SIComposite‡ 5.1 	 0.2 5.8 	 0.3 6.7 	 0.5* 0.007
Insulin secretion
ISR AUC  10
3 30.0 	 0.9 28.1 	 0.8 25.4 	 1.2* 0.01
-Cell responsivity (
o) (10
9/min) 13.7 	 0.84 13.3 	 0.4* 11.5 	 0.7* 0.02
Insulin clearance (IC)
IC1 (ISR AUC/insulin AUC) 2.8 	 0.1 3.1 	 0.1* 3.2 	 0.1* 0.001
IC2 (C-peptide AUC/insulin AUC) 47.8 	 1.1 53.3 	 1.4* 55.9 	 2.3* 0.001
Data are means 	 SE or n (%). ANCOVA was used to adjust for age, race, and BMI. *P  0.05 vs. E/E; †P  0.05 vs. E/E and E/K using Tukey’s
test for post hoc analyses. †SIMM 
 insulin sensitivity from glucose minimal model (25). ‡SIComposite 
 insulin sensitivity from Matsuda (23).
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ity is not clear. Kir6.2 is expressed in multiple tissues,
including skeletal muscle, brain, and heart. The increase in
insulin sensitivity could be due to direct effects of the
altered KATP channel activity in one or more of these
tissues, and a link between the KATP channel in the
hypothalamus and the liver has recently been established
(40). An increase in activation of KATP channels in the
hypothalamus decreases hepatic gluconeogenesis, and
this central effect could serve to counterbalance periph-
eral actions to maintain glucose homeostasis (40,41). It is
interesting to note that basal and insulin-stimulated mus-
cle glucose transport is increased in Kir6.2-null mice,
which suggests a role for this channel in the regulation of
muscle glucose metabolism (10).
Whether the enhanced insulin sensitivity results from
direct effects of KATP channel activity in muscle or is
secondary to effects on insulin secretion is unclear. There
is precedent for an increase in insulin sensitivity second-
ary to reduction in insulin secretion. In the evolution of
type 1 diabetes, insulin secretion is reduced before glu-
cose levels rise (42), and increased insulin sensitivity has
been demonstrated in normoglycemic carriers of HNF1
mutations with reduced insulin secretion prior to diabetes
onset (43). These observations, coupled with those of the
present study, suggest that in the evolution of type 2
diabetes, increased insulin sensitivity may compensate for
a reduction in insulin secretion, resulting in normal glu-
cose tolerance. Over time, glucose intolerance develops
due to progression in the severity of the secretion defect
and/or exposure to factors that reduce insulin sensitivity.
However, we also cannot completely exclude the likeli-
hood that these E23K variants have not developed diabe-
tes because of their increased insulin sensitivity. In such
cases, it might reﬂect a feature of nondiabetic E23K
variants rather than of subjects with E23K variants, per se.
Although Kir6.2 levels are high in pancreatic -cells, we
did not ﬁnd differences in glucagon secretion. An addi-
tional new ﬁnding is the association of E23K variant with
an increase in insulin clearance, as demonstrated in study
2. An increase in insulin clearance may contribute to the
reduction in peripheral insulin concentrations that is due
largely to the decrease in insulin secretion. The liver is the
major site of insulin clearance under physiologic circum-
stances, and this change in insulin clearance is likely due
to a change in hepatic insulin metabolism (44). A link
between hepatic insulin receptor binding and action and
degradation by the liver has been reported (45).
Molecular basis of the E23K phenotype. In heterolo-
gous expression studies, reconstituted E23K channels
exhibit a mild, yet signiﬁcant, decrease in ATP sensitivity
and a relative increase in basal activity in the intact cell. In
the -cell, decreased ATP inhibition and consequent chan-
nel overactivity is predicted to suppress glucose sensing.
In contrast to activating mutations in Kir6.2 that underlie
NDM (28), the E23K variant has a less radical effect on
channel activity and is associated with type 2 diabetes.
The molecular consequence of the E23K variant has
been controversial. Given the high KATP channel density in
-cells, it is predicted that a change in KATP channel
activity (1%) could signiﬁcantly affect insulin secretion,
and, therefore, subtle effects of E23K on channel activity
could be physiologically relevant. In support of the con-
clusion that E23K does not alter channel activity, whole-
cell K
-currents were similar in Xenpous oocytes
expressing E/E or K/K channels (4). A subsequent study
(6) reported an increase in ATP sensitivity of K/K chan-
nels, relative to E/E, but a subsequent decrease in ATP
inhibition upon application of long-chain acyl-CoAs. The
most detailed study was carried out by Schwanstecher and
colleagues (5,46). Our data parallel their initial ﬁndings of an
approximately twofold reduction in ATP sensitivity and
increase in open probability and reduced sulfonylurea sensi-
tivity (46) associated with the E23K variant. The similarity of
our ﬁndings, in a completely independent study, utilizing
different methodologies to assess open probability, strongly
supports the conclusion that the E23K variant decreases ATP
inhibition of the KATP channel.
Mechanistically, the observed increase in open proba-
bility can account for both the reduced insulin secretion
and decrease in sulfonylurea inhibition of E23K channels.
Whether the E23K variant affects sulfonylurea dosing is
unknown, but it is notable that the E23K variant is associated
with risk for secondary failure to sulfonylureas in type 2
diabetic patients (47,48), and human islets isolated from
E23K donors (E/K and K/K) exhibit a decrease in sulfonylu-
rea-induced insulin secretion (47).
Conclusions. Subjects with the Kir6.2 E23K variant have
multiple insulin secretory defects to glucose and de-
creased responsiveness of the -cell over a physiologic
range of glucose concentrations, and these can be ex-
plained by the molecular properties of the E23K channels.
These defects in insulin secretion are accompanied by an
increase in insulin sensitivity, possibly a compensatory
response to reduced insulin secretion. The -cell secretory
defects are present prior to diabetes onset and are likely
responsible for the increased risk of type 2 diabetes in
subjects with the at-risk E23K genotypes, if superimposed
on lifestyle factors causing insulin resistance.
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